Department of Molecular Cell Biology and Toxicology, Jiangsu Key Lab of Cancer Biomarkers, Prevention & Treatment, Cancer Center; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.
PLoS One. 2013 Aug 19;8(8):e71140. doi: 10.1371/journal.pone.0071140. eCollection 2013.
To investigate the association of SOX2 expression in tumor with clinicopathological features and survival of non-small-cell lung carcinoma (NSCLC) patients.
Publications assessing the clinicopathological characteristics and prognostic significance of SOX2 in NSCLC were identified up to May 2013. A meta-analysis of eligible studies was performed using standard statistical methods to clarify the association between SOX2 expression and these clinical parameters.
A total of eight studies met the inclusion criteria. Analysis of these data showed that SOX2 expression was positively associated with squamous histology, (pooled OR = 5.26, 95% CI: 1.08-25.6, P = 0.040). Simultaneously, we also found that SOX2 expression was positively associated with overall survival (pooled HR = 0.65, 95% CI: 0.47-0.89, P = 0.007, random-effect).
SOX2 expression in tumor is a candidate positive prognostic biomarker for NSCLC patients.
探讨 SOX2 表达与非小细胞肺癌（NSCLC）患者临床病理特征和生存的关系。
检索截至 2013 年 5 月评估 SOX2 在 NSCLC 中临床病理特征和预后意义的出版物。采用标准统计学方法对合格研究进行荟萃分析，以明确 SOX2 表达与这些临床参数之间的关联。
共有 8 项研究符合纳入标准。对这些数据的分析表明，SOX2 表达与鳞状组织学呈正相关（合并 OR=5.26，95%CI：1.08-25.6，P=0.040）。同时，我们还发现 SOX2 表达与总生存期呈正相关（合并 HR=0.65，95%CI：0.47-0.89，P=0.007，随机效应）。
肿瘤中 SOX2 的表达是 NSCLC 患者的一个候选阳性预后生物标志物。
